VerÃ³nica GonzÃ¡lez-Calle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5025915/publications.pdf

Version: 2024-02-01

42	632	758635	610482
papers	citations	12 h-index	24 g-index

43	43	43	1026
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020, 10, 102.	2.8	126
2	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	3.3	108
3	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	2.8	60
4	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood, 2019, 134, 781-781.	0.6	38
5	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica, 2017, 102, 922-931.	1.7	34
6	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Annals of Hematology, 2018, 97, 1453-1462.	0.8	26
7	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia, 2016, 30, 2026-2031.	3.3	19
8	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.	2.5	18
9	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer Journal, 2020, 10, 14.	2.8	16
10	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	2.8	14
11	Liquid biopsy: a nonâ€invasive approach for Hodgkin lymphoma genotyping. British Journal of Haematology, 2021, 195, 542-551.	1.2	14
12	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. International Journal of Molecular Sciences, 2022, 23, 5570.	1.8	14
13	Smoldering Multiple Myeloma: Who and When to Treat. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 716-722.	0.2	13
14	Monoclonal gammopathy of renal significance (MGRS): Realâ€world data on outcomes and prognostic factors. American Journal of Hematology, 2022, 97, 877-884.	2.0	12
15	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. Blood Cancer Journal, 2019, 9, 52.	2.8	11
16	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2020, 22, 60-71.	1.2	11
17	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	2.0	11
18	EHA evaluation of the ESMOâ€”Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	2.0	10

#	Article	IF	Citations
19	Timing of treatment of smoldering myeloma: early treatment. Blood Advances, 2018, 2, 3045-3049.	2.5	9
20	Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. European Journal of Internal Medicine, 2018, 58, 57-63.	1.0	9
21	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 486-492.e1.	0.2	7
22	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers, 2020, 12, 3615.	1.7	7
23	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	1.2	7
24	Drugâ€induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. HemaSphere, 2019, 3, e192.	1.2	6
25	Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stemâ€cell transplantation is a prognostic marker of longer progressionâ€free survival and overall survival. British Journal of Haematology, 2022, 198, 278-287.	1.2	6
26	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 621-630.	0.2	5
27	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. Blood, 2019, 134, 694-694.	0.6	4
28	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	0.6	3
29	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. Blood Cancer Journal, 2021, 11, 11.	2.8	3
30	A safety profile of medications used to treat WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Opinion on Drug Safety, 2018, 17, 609-621.	1.0	2
31	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e47.	0.2	2
32	Exportinâ€1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. Hematological Oncology, 2019, 37, 215-218.	0.8	2
33	Is there a role for new drugs with alkylating properties in multiple myeloma?. Lancet Haematology,the, 2020, 7, e357-e359.	2.2	2
34	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. Clinical Case Reports (discontinued), 2016, 4, 1096-1100.	0.2	1
35	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. Blood, 2018, 132, 4446-4446.	0.6	1
36	Targeted therapy and maintenance in myeloma. British Medical Bulletin, 2017, 122, 163-178.	2.7	0

#	Article	IF	Citations
37	Prognostic Factors in Systemic Light-Chain Amyloidosis with Cardiac Involvement. Single Center Experience at the University Hospital of Salamanca. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S328.	0.2	0
38	Improving the conditioning regimen in multiple myeloma. Lancet Haematology,the, 2019, 6, e234-e235.	2.2	0
39	Recovery of policlonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e176-e177.	0.2	0
40	Dexamethasone as a partner of isatuximab. Blood, 2021, 137, 1133-1134.	0.6	0
41	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. Blood, 2016, 128, 3452-3452.	0.6	0
42	Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN). Blood, 2016, 128, 4482-4482.	0.6	0